Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Tocilizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02721004

ML22551

Details and patient eligibility

About

This is an open-label, non-interventional study to evaluate efficacy and safety in rheumatoid arthritis participants receiving tocilizumab as per the product label.

Enrollment: 592 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with rheumatoid arthritis receiving tocilizumab as per product label

Exclusion criteria

• No specific exclusion criteria were specified for this non-interventional trial

Trial design

592 participants in 1 patient group

Rheumatoid arthritis participants

Description:

Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.

Treatment:

Drug: Tocilizumab